helicase primase

Pritelivir (BAY 57-1293) (BAY 57-1293) is a potent helicase-primase inhibitor with active against HSV-1 and HSV-2 (IC50: 20 nM).

Amenamevir (ASP2151) is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2 (EC50: 14 ng/mL).

Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (IC50: 0.02 μM against HSV1-2). Pritelivir mesylate hydrate is an inhibitor of the viral helicase-primase complex. Pritelivir mesylate hydrate shows antiviral activity in vit

Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (IC50: 0.02 μM against HSV1-2). Pritelivir mesylate is an inhibitor of the viral helicase-primase complex. Pritelivir mesylate shows antiviral activity in vitro and in animal models

HSV-1-IN-1 (compound 1b) is a candidate drug for HSV-1 (IC50=0.5 nM) and HSV-2 (IC50=16 nM) infections. It inhibits the helicase-primase complex to prevent viral replication, thus suppressing HSV infection.

HSV-1/HSV-2-IN-3 inhibits the helicase-primase complex of herpes simplex virus (HSV), interfering with the crucial processes of DNA unwinding and primer synthesis necessary for viral genome replication. In gD immunofluorescence assays containing 2% FBS, its EC50 against HSV-2 is 7.0 nM, while in assays with 10% human serum, the EC50 is 57.5 nM. Within qPCR replication analysis, the compound demonstrates an EC50 of 1.1 nM. Additionally, HSV-1/HSV-2-IN-3 exhibits strong selectivity against off-target interactions with human carbonic anhydrase (IC50 for hCA II ≈ 2.9 µM, and > 35 µM for hCA I). This compound is applicable in anti-HSV research.

RA-0002323-01 is an antiviral agent targeting the viral helicase-primase (helicase-primase), derived from the Heli-SMACC (small molecule assembly targeting helicase).